The Dialive device significantly reduced severity of endotoxemia and improved albumin function in patients with acute-on-chronic liver failure and appears safe with careful patient monitoring, according to data in the Journal of Hepatology.
“Dialive is a novel liver dialysis device invented at University College London,” Rajiv Jalan, PhD, lead investigator and professor of hepatology
Acute-on-chronic liver failure (ACLF) occurs in 30% of hospitalized cirrhosis patients, leading to over one million deaths worldwide each year. Currently, the only potential treatment for this condition is liver transplantation, which is available to very few patients. A first-in-human randomized controlled clinical trial using DIALIVE, a novel liver dialysis device, demonstrated its potential as a disease-modifying therapy and resolved liver failure significantly faster and in a greater p.
FRIDAY, June 2, 2023 (HealthDay News) A new liver dialysis device might soon be able to save patients on the edge of death from liver failure, early clinical trial
The first successful in-patient trial of liver dialysis has been completed by researchers from UCL, the Royal Free Hospital, UCL spin-out Yaqrit and their collaborators.